Captor Therapeutics Spolka Akcyjna Past Earnings Performance
Past criteria checks 0/6
Captor Therapeutics Spolka Akcyjna's earnings have been declining at an average annual rate of -23.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 56.5% per year.
Key information
-23.9%
Earnings growth rate
-18.9%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | 56.5% |
| Return on equity | -100.1% |
| Net Margin | -212.6% |
| Next Earnings Update | 28 Nov 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Jul 13
We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn
Oct 03Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 13Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth
Jun 15Revenue & Expenses Breakdown
How Captor Therapeutics Spolka Akcyjna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 19 | -41 | 17 | 44 |
| 30 Jun 24 | 19 | -47 | 20 | 49 |
| 31 Mar 24 | 16 | -66 | 20 | 61 |
| 31 Dec 23 | 13 | -71 | 22 | 65 |
| 30 Sep 23 | 13 | -66 | 12 | 74 |
| 30 Jun 23 | 11 | -58 | 17 | 64 |
| 31 Mar 23 | 10 | -39 | 20 | 51 |
| 31 Dec 22 | 9 | -36 | 24 | 44 |
| 30 Sep 22 | 5 | -40 | 40 | 27 |
| 30 Jun 22 | 5 | -41 | 38 | 28 |
| 31 Mar 22 | 5 | -38 | 35 | 25 |
| 31 Dec 21 | 4 | -33 | 31 | 23 |
Quality Earnings: CTX is currently unprofitable.
Growing Profit Margin: CTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CTX is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare CTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: CTX has a negative Return on Equity (-100.1%), as it is currently unprofitable.